IRADIMED CORP (IRMD) Stock Fundamental Analysis
USA - NASDAQ:IRMD - US46266A1097 - Common Stock
77.06 USD
+2.69 (+3.62%)
Overall IRMD gets a fundamental rating of 7 out of 10. We evaluated IRMD against 191 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IRMD a very profitable company, without any liquidiy or solvency issues. IRMD is not valued too expensively and it also shows a decent growth rate. This makes IRMD very considerable for quality investing!
1. Profitability
1.1 Basic Checks
IRMD had positive earnings in the past year.
IRMD had a positive operating cash flow in the past year.
In the past 5 years IRMD has always been profitable.
Each year in the past 5 years IRMD had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 19.41%, IRMD belongs to the top of the industry, outperforming 97.91% of the companies in the same industry.
The Return On Equity of IRMD (21.91%) is better than 93.72% of its industry peers.
IRMD has a better Return On Invested Capital (19.30%) than 97.38% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IRMD is significantly above the industry average of 9.00%.
The 3 year average ROIC (18.78%) for IRMD is below the current ROIC(19.30%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.41% | ||
| ROE | 21.91% | ||
| ROIC | 19.3% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 26.61%, IRMD belongs to the best of the industry, outperforming 94.76% of the companies in the same industry.
IRMD's Profit Margin has been stable in the last couple of years.
IRMD's Operating Margin of 30.67% is amongst the best of the industry. IRMD outperforms 97.38% of its industry peers.
In the last couple of years the Operating Margin of IRMD has grown nicely.
IRMD's Gross Margin of 76.96% is amongst the best of the industry. IRMD outperforms 89.01% of its industry peers.
In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.67% | ||
| PM (TTM) | 26.61% | ||
| GM | 76.96% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
IRMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, IRMD has more shares outstanding
Compared to 5 years ago, IRMD has more shares outstanding
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 49.80 indicates that IRMD is not in any danger for bankruptcy at the moment.
IRMD has a Altman-Z score of 49.80. This is amongst the best in the industry. IRMD outperforms 98.95% of its industry peers.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 49.8 |
ROIC/WACC2.19
WACC8.82%
2.3 Liquidity
A Current Ratio of 8.78 indicates that IRMD has no problem at all paying its short term obligations.
IRMD's Current ratio of 8.78 is amongst the best of the industry. IRMD outperforms 90.58% of its industry peers.
IRMD has a Quick Ratio of 7.51. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
IRMD has a Quick ratio of 7.51. This is amongst the best in the industry. IRMD outperforms 90.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.78 | ||
| Quick Ratio | 7.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.25% over the past year.
Measured over the past years, IRMD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.92% on average per year.
The Revenue has grown by 11.74% in the past year. This is quite good.
Measured over the past years, IRMD shows a quite strong growth in Revenue. The Revenue has been growing by 13.71% on average per year.
EPS 1Y (TTM)11.25%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
Revenue 1Y (TTM)11.74%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%13.84%
3.2 Future
Based on estimates for the next years, IRMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.71% on average per year.
IRMD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.02% yearly.
EPS Next Y14.36%
EPS Next 2Y12.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year10.65%
Revenue Next 2Y11.02%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
IRMD is valuated quite expensively with a Price/Earnings ratio of 43.29.
IRMD's Price/Earnings ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 69.63% of the companies in the same industry.
When comparing the Price/Earnings ratio of IRMD to the average of the S&P500 Index (27.76), we can say IRMD is valued expensively.
Based on the Price/Forward Earnings ratio of 36.76, the valuation of IRMD can be described as expensive.
71.20% of the companies in the same industry are more expensive than IRMD, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of IRMD to the average of the S&P500 Index (23.21), we can say IRMD is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.29 | ||
| Fwd PE | 36.76 |
4.2 Price Multiples
IRMD's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 69.63% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IRMD is valued a bit cheaper than 72.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 73.52 | ||
| EV/EBITDA | 36.3 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IRMD does not grow enough to justify the current Price/Earnings ratio.
IRMD has an outstanding profitability rating, which may justify a higher PE ratio.
IRMD's earnings are expected to grow with 12.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.01
PEG (5Y)3.11
EPS Next 2Y12.71%
EPS Next 3YN/A
5. Dividend
5.1 Amount
IRMD has a yearly dividend return of 0.93%, which is pretty low.
Compared to an average industry Dividend Yield of 1.79, IRMD pays a better dividend. On top of this IRMD pays more dividend than 93.19% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, IRMD's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.93% |
5.2 History
IRMD has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
IRMD pays out 39.33% of its income as dividend. This is a sustainable payout ratio.
DP39.33%
EPS Next 2Y12.71%
EPS Next 3YN/A
NASDAQ:IRMD (10/8/2025, 10:38:02 AM)
77.06
+2.69 (+3.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners59.43%
Inst Owner Change0%
Ins Owners36.81%
Ins Owner Change0.67%
Market Cap980.20M
Analysts82.5
Price Target74.97 (-2.71%)
Short Float %1.92%
Short Ratio3.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.93% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.33%
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.43%
Min EPS beat(2)0.43%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)4.6%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)6.12%
EPS beat(12)10
Avg EPS beat(12)7.27%
EPS beat(16)14
Avg EPS beat(16)11.73%
Revenue beat(2)1
Avg Revenue beat(2)-0.52%
Min Revenue beat(2)-1.05%
Max Revenue beat(2)0.01%
Revenue beat(4)1
Avg Revenue beat(4)-0.62%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)0.01%
Revenue beat(8)3
Avg Revenue beat(8)-0.43%
Revenue beat(12)5
Avg Revenue beat(12)-0.16%
Revenue beat(16)7
Avg Revenue beat(16)-0.07%
PT rev (1m)0%
PT rev (3m)3.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.75%
EPS NY rev (1m)0%
EPS NY rev (3m)6.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.77%
Revenue NY rev (1m)-1.09%
Revenue NY rev (3m)1.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.29 | ||
| Fwd PE | 36.76 | ||
| P/S | 12.63 | ||
| P/FCF | 73.52 | ||
| P/OCF | 36.11 | ||
| P/B | 10.39 | ||
| P/tB | 10.78 | ||
| EV/EBITDA | 36.3 |
EPS(TTM)1.78
EY2.31%
EPS(NY)2.1
Fwd EY2.72%
FCF(TTM)1.05
FCFY1.36%
OCF(TTM)2.13
OCFY2.77%
SpS6.1
BVpS7.41
TBVpS7.15
PEG (NY)3.01
PEG (5Y)3.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.41% | ||
| ROE | 21.91% | ||
| ROCE | 24.39% | ||
| ROIC | 19.3% | ||
| ROICexc | 42.22% | ||
| ROICexgc | 45.68% | ||
| OM | 30.67% | ||
| PM (TTM) | 26.61% | ||
| GM | 76.96% | ||
| FCFM | 17.17% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexcg growth 3Y-6.9%
ROICexcg growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score4
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1738.97% | ||
| Cap/Sales | 17.79% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 110.32% | ||
| Profit Quality | 64.54% | ||
| Current Ratio | 8.78 | ||
| Quick Ratio | 7.51 | ||
| Altman-Z | 49.8 |
F-Score4
WACC8.82%
ROIC/WACC2.19
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)11.25%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%16.67%
EPS Next Y14.36%
EPS Next 2Y12.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.74%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%13.84%
Revenue Next Year10.65%
Revenue Next 2Y11.02%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.02%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y86.2%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y79.39%
OCF growth 3Y31.53%
OCF growth 5Y20.16%